Although motor disturbances parallel the course of dementia, worsening both quality of life and social costs, the pathogenesis remains still unclear.
Objective:
Through the combination of cerebrospinal fluid (CSF) biomarkers assessment and transcranial magnetic stimulation (TMS) protocols, here we provided a cross-sectional study to understand pathogenic mechanisms of Alzheimer’s disease (AD)-related early motor disturbances.
Methods:
The motor phenotype, as defined with Unified Parkinson’s Disease Rating Scale (UPDRS) part 2-3, Rating Scale for Gait Evaluation in Cognitive Deterioration (RSEGCD) and Tinetti scale, together with CSF profile of amyloid-β 42 (Aβ42), total-tau, and phosphorylated-tau were determined in 37 AD patients and compared to 18 patients with vascular dementia (VaD). A TMS protocol of short afferent inhibition (SAI) was further applied on a subset of AD patients. Clinical, biochemical, and neurophysiological data were then compared and correlated in order to find significant associations.
Results:
AD patients exhibited subtle locomotor impairment and slight extrapyramidal signs. Main motor features (UPDRS part 3, RSGECD, and Tinetti scale scores) correlate with Aβ42 levels but not with t-tau and p-tau. AD patients also presented SAI impairment directly related to UPDRS part 3 score and Aβ42 levels. Motor disturbances of VaD group did not differ statistically from AD and did not correlate with CSF biomarkers.
Conclusions:
The association of motor disturbances with low Aβ42 CSF levels and individual SAI suggests that amyloid-mediated degeneration of cholinergic system may account for early AD-related motor impairment, providing interesting insights either for frailty stratification of patients or personalized therapies.
ScarmeasN, HadjigeorgiouGM, PapadimitriouA, DuboisB, SarazinM, BrandtJ, AlbertM, MarderK, BellK, HonigLS, WegesinD, SternY (2004) Motor signs during the course of Alzheimer disease. Neurology63, 975–982.
6.
Montero-OdassoM, Pieruccini-FariaF, BarthaR, BlackSE, FingerE, FreedmanM, GreenbergB, GrimesDA, HegeleRA, HudsonC, KleinstiverPW, LangAE, MasellisM, McLaughlinPM, MunozDP, StrotherS, SwartzRH, SymonsS, TartagliaMC, ZinmanL, StrongMJ, ONDRIInvestigators, McIlroyW (2017) Motor phenotype in neurodegenerative disorders: Gait and balance platform study design protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). J Alzheimers Dis59, 707–721.
7.
PortetF, ScarmeasN, CosentinoS, HelznerEP, SternY (2009) Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol66, 1120–1126.
8.
AllaliG, AnnweilerC, BlumenHM, CallisayaML, De CockA-M, KressigRW, SrikanthV, SteinmetzJ-P, VergheseJ, BeauchetO (2016) Gait phenotype from mild cognitive impairment to moderate dementia: Results from the GOOD initiative. Eur J Neurol23, 527–541.
9.
ScheltensP, BlennowK, BretelerMMB, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 505–517.
10.
KochG, Di LorenzoF, Del OlmoMF, BonníS, PonzoV, CaltagironeC, BozzaliM, MartoranaA (2015) Reversal of LTP-like cortical plasticity in Alzheimer’s disease patients with tau-related faster clinical progression. J Alzheimers Dis50, 605–616.
11.
SeppäläTT, KoivistoAM, HartikainenP, HelisalmiS, SoininenH, HerukkaS-K (2011) Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis25, 583–594.
12.
BlennowK, BiscettiL, EusebiP, ParnettiL (2016) Cerebrospinal fluid biomarkers in Alzheimer’s and Parkinson’s diseases-From pathophysiology to clinical practice. Mov Disord31, 836–847.
13.
TokimuraH, Di LazzaroV, TokimuraY, OlivieroA, ProficeP, InsolaA, MazzoneP, TonaliP, RothwellJC (2000) Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol523(Pt 2), 503–513.
14.
Di LazzaroV, OlivieroA, ProficeP, PennisiMA, Di GiovanniS, ZitoG, TonaliP, RothwellJC (2000) Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res135, 455–461.
15.
Di LazzaroV, OlivieroA, TonaliPA, MarraC, DanieleA, ProficeP, SaturnoE, PilatoF, MasulloC, RothwellJC (2002) Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology59, 392–397.
16.
Di LorenzoF, MartoranaA, PonzoV, BonníS, D’AngeloE, CaltagironeC, KochG (2013) Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer’s disease patients. Front Aging Neurosci5, 2.
17.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
BalasaM, Sánchez-ValleR, AntonellA, BoschB, OlivesJ, RamiL, CastellvíM, MolinuevoJL, LladóA (2014) Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. J Alzheimers Dis40, 919–927.
20.
Martínez-MartínP, Osa-RuizE, Gómez-ConesaA, OlazaránJ, RSGE-CDValidation Group (2012) A rating scale for gait evaluation in cognitive deterioration (RSGE-CD): Validation study. J Alzheimers Dis31, 543–553.
21.
SchirinziT, SancesarioGM, IalongoC, ImbrianiP, MadeoG, TonioloS, MartoranaA, PisaniA (2015) A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. Front Neurol6, 86.
22.
SancesarioGM, EspositoZ, NuccetelliM, BernardiniS, SorgeR, MartoranaA, FedericiG, BernardiG, SancesarioG (2010) Abeta1-42 detection in CSF of Alzheimer’s disease is influenced by temperature: Indication of reversible Abeta1-42 aggregation?Exp Neurol223, 371–376.
TinettiME, WilliamsTF, MayewskiR (1986) Fall risk index for elderly patients based on number of chronic disabilities. Am J Med80, 429–434.
25.
BeauchetO, AllaliG, BerrutG, HommetC, DubostV, AssalF (2008) Gait analysis in demented subjects: Interests and perspectives. Neuropsychiatr Dis Treat4, 155–160.
26.
MartoranaA, EspositoZ, Di LorenzoF, GiacobbeV, SancesarioGM, BucchiG, BonníS, BernardiniS, SorgeR, SancesarioG, BernardiG, CaltagironeC, KochG (2012) Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer’s disease patients. J Neural Transm119, 771–778.
27.
KochG, Di LorenzoF, BonníS, GiacobbeV, BozzaliM, CaltagironeC, MartoranaA (2014) Dopaminergic modulation of cortical plasticity in Alzheimer’s disease patients. Neuropsychopharmacology39, 2654–2661.
28.
ŠimićG, Babić LekoM, WrayS, HarringtonCR, DelalleI, Jovanov-MiloševićN, BažadonaD, BuéeL, de SilvaR, Di GiovanniG, WischikCM, HofPR (2017) Monoaminergic neuropathology in Alzheimer’s disease. Prog Neurobiol151, 101–138.
29.
TrilloL, DasD, HsiehW, MedinaB, MoghadamS, LinB, DangV, SanchezMM, De MiguelZ, AshfordJW, SalehiA (2013) Ascending monoaminergic systems alterations in Alzheimer’s disease. translating basic science into clinical care. Neurosci Biobehav Rev37, 1363–1379.
30.
Del CampoN, PayouxP, DjilaliA, DelrieuJ, HoogendijkEO, RollandY, CesariM, WeinerMW, AndrieuS, VellasB, MAPT/DSA Study Group (2016) Relationship of regional brain β-amyloid to gait speed. Neurology86, 36–43.
LiuY, SternY, ChunMR, JacobsDM, YauP, GoldmanJE (1997) Pathological correlates of extrapyramidal signs in Alzheimer’s disease. Ann Neurol41, 368–374.
33.
CollobySJ, McParlandS, O’BrienJT, AttemsJ (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain135, 2798–2808.
34.
RochesterL, YarnallAJ, BakerMR, DavidRV, LordS, GalnaB, BurnDJ (2012) Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain135, 2779–2788.
35.
JenkinsonN, NandiD, MuthusamyK, RayNJ, GregoryR, SteinJF, AzizTZ (2009) Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord24, 319–328.
36.
KarachiC, GrabliD, BernardFA, TandéD, WattiezN, BelaidH, BardinetE, PrigentA, NothackerH-P, HunotS, HartmannA, LehéricyS, HirschEC, FrançoisC (2010) Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest120, 2745–2754.
37.
PelosinE, OgliastroC, LagravineseG, BonassiG, MirelmanA, HausdorffJM, AbbruzzeseG, AvanzinoL (2016) Attentional control of gait and falls: Is cholinergic dysfunction a common substrate in the elderly and Parkinson’s disease?Front Aging Neurosci8, 104.
Baker-NighA, VahediS, Goetz DavisE, WeintraubS, BigioEH, KleinWL, GeulaC, BinderL (2015) Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain138, 1722–1737.
40.
ChiaravallotiA, BarbagalloG, RicciM, MartoranaA, UrsiniF, SanninoP, KaralisG, SchillaciO (2018) Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer’s disease patients: A CSF and FDG PET study. Brain Res1678, 116–122.
41.
LiS-C, RieckmannA (2014) Neuromodulation and aging: Implications of aging neuronal gain control on cognition. Curr Opin Neurobiol29, 148–158.
42.
VergheseJ, LiptonRB, HallCB, KuslanskyG, KatzMJ, BuschkeH (2002) Abnormality of gait as a predictor of non-Alzheimer’s dementia. N Engl J Med347, 1761–1768.
